Prospective phase II Study on 5-days azacitidine for treatment of symptomatic and/or erythropoietin unresponsive patients with low/INT-1-risk myelodysplastic syndromes.

doi:10.1158/1078-0432.CCR-12-3540

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Prospective phase II Study on 5-days azacitidine for treatment of symptomatic and/or erythropoietin unresponsive patients with low/INT-1-risk myelodysplastic syndromes.

Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Jun 2013

Filì Carla, Malagola Michele, Follo Matilde Y, Finelli Carlo, Iacobucci Ilaria, Martinelli Giovanni, Cattina Federica, Clissa Cristina, Candoni Anna, Fanin Renato, Gobbi Marco, Bocchia Monica, Defina Marzia, Spedini Pierangelo, Skert Cristina, Manzoli Lucia, Cocco Lucio, Russo Domenico

Abstract excerpt

PURPOSE: This phase II prospective study aimed to evaluate the efficacy and safety of 5-days azacytidine (5d-AZA) in patients with low-risk myelodysplastic syndromes (MDS). Second, single-nucleotide polymorphism (SNP) genetic profile and phosphoinositide-phospholipase C (PI-PLC) β1 levels were studied to evaluate possible biologic markers able to predict the hematologic response. EXPERIMENTAL DESIGN: The study...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Azacitidine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Administration Schedule

Share to Erythropoietin

Share to Gene Expression Regulation, Neoplastic

Share to Hematologic Tests

Share to Myelodysplastic Syndromes

Share to Phospholipase C beta

Share to Wnt1 Protein

Source

Open in PubMed

Identifiers

PMID: 23596104
DOI: 10.1158/1078-0432.CCR-12-3540

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Prospective phase II Study on 5-days azacitidine for treatment of symptomatic and/or erythropoietin unresponsive patients with low/INT-1-risk myelodysplastic syndromes.PMID 23596104Read ↗

Limited clinical efficacy of azacitidine in transfusion-dependent, growth factor-resistant, low- and Int-1-risk MDS: Results from the nordic NMDSG08A phase II trialSemantic proximity Read ↗

A randomized phase II trial of azacitidine +/- epoetin-β in lower-risk myelodysplastic syndromes resistant to erythropoietic stimulating agents.Semantic proximity Read ↗

Phase I combination trial of lenalidomide and azacitidine in patients with higher-risk myelodysplastic syndromes.Semantic proximity Read ↗

Predicting outcome in higher-risk myelodysplastic syndrome patients treated with azacitidine.Semantic proximity Read ↗

An increased expression of PI-PLCβ1 is associated with myeloid differentiation and a longer response to azacitidine in myelodysplastic syndromesSemantic proximity Read ↗

Real-world Effectiveness of Azacitidine in Treatment-Naive Patients With Higher-risk Myelodysplastic Syndromes.Semantic proximity Read ↗

PI-PLCβ-1 and activated Akt levels are linked to azacitidine responsiveness in high-risk myelodysplastic syndromesSemantic proximity Read ↗

Survival of myelodysplastic syndrome patients after azacitidine therapy.Semantic proximity Read ↗

Efficacy and safety of extended dosing schedules of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromesSemantic proximity Read ↗

Synergistic induction of PI-PLCβ1 signaling by azacitidine and valproic acid in high-risk myelodysplastic syndromesSemantic proximity Read ↗

Key clinical observations after 5-azacytidine and decitabine treatment of myelodysplastic syndromes suggest practical solutions for better outcomesSemantic proximity Read ↗

New Ways to Use DNA Methyltransferase Inhibitors for the Treatment of Myelodysplastic SyndromeSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.